These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 42344)

  • 1. Clinical pharmacology of mephenytoin and ethotoin.
    Troupin AS; Friel P; Lovely MP; Wilensky AJ
    Ann Neurol; 1979 Nov; 6(5):410-4. PubMed ID: 42344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The metabolism of 3-methyl-5-ethyl-5-phenylhydantoin (mephenytoin) to 5-ethyl-5-phenylhydantoin (Nirvanol) in mice in relation to anticonvulsant activity.
    Kupferberg HJ; Yonekawa W
    Drug Metab Dispos; 1975; 3(1):26-9. PubMed ID: 234831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of mephenytoin (3-methyl-5-ethyl-5-phenylhydantoin) and its demethylated metabolite by selective ion monitoring.
    Yonekawa W; Kupferberg HJ
    J Chromatogr; 1979 Jun; 163(2):161-7. PubMed ID: 541367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enantioselective pharmacokinetics of ethotoin in humans following single oral doses of the racemate.
    Hooper WD; O'Shea NJ; Qing MS
    Chirality; 1992; 4(3):142-7. PubMed ID: 1350205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Determination of phenobarbital, mephenytoin and diphenylhydantoin in the surveillance of anticonvulsant treatment].
    Maitrot B; Hue G; Canonne MA; Rocher A; Landriau N
    Ann Biol Clin (Paris); 1976; 34(2):107-12. PubMed ID: 9890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man.
    Küpfer A; Desmond PV; Schenker S; Branch RA
    J Pharmacol Exp Ther; 1982 Jun; 221(3):590-7. PubMed ID: 7086673
    [No Abstract]   [Full Text] [Related]  

  • 7. A major pathway of mephenytoin metabolism in man. Aromatic hydroxylation to p-hydroxymephenytoin.
    Küpfer A; Brilis GM; Watson JT; Harris TM
    Drug Metab Dispos; 1980; 8(1):1-4. PubMed ID: 6102023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects.
    Wedlund PJ; Aslanian WS; Jacqz E; McAllister CB; Branch RA; Wilkinson GR
    J Pharmacol Exp Ther; 1985 Sep; 234(3):662-9. PubMed ID: 4032286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-dependent kinetics of ethotoin in man.
    Sjö ; Hvidberg EF; Larsen NE; Naestoft J
    Clin Exp Pharmacol Physiol; 1975; 2(3):185-92. PubMed ID: 238776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography.
    Wedlund PJ; Sweetman BJ; McAllister CB; Branch RA; Wilkinson GR
    J Chromatogr; 1984 Apr; 307(1):121-7. PubMed ID: 6725478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased systemic availability of drugs during acute ethanol intoxication: studies with mephenytoin in the dog.
    Zysset T; Preisig R; Bircher J
    J Pharmacol Exp Ther; 1980 Apr; 213(1):173-8. PubMed ID: 7188964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydantoin-induced teratogenesis: are arene oxide intermediates really responsible?
    Finnell RH; DiLiberti JH
    Helv Paediatr Acta; 1983 May; 38(2):171-7. PubMed ID: 6135678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mephenytoin: a reappraisal.
    Troupin AS; Ojemann LM; Dodrill CB
    Epilepsia; 1976 Dec; 17(4):403-14. PubMed ID: 1001284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiopyrine half-life as a measure of hepatic enzyme induction: clinical applications in a chronic epileptic population.
    Byrne E; Harman AW; Frewin DB; Hallpike JF
    Clin Exp Neurol; 1979; 16():183-9. PubMed ID: 550940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic rationale for three times daily administration of ethotoin (Peganone).
    Browne TR; Szabo GK
    J Clin Pharmacol; 1989 Mar; 29(3):270-1. PubMed ID: 2566627
    [No Abstract]   [Full Text] [Related]  

  • 16. Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans.
    Küpfer A; Patwardhan R; Ward S; Schenker S; Preisig R; Branch RA
    J Pharmacol Exp Ther; 1984 Jul; 230(1):28-33. PubMed ID: 6747829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for the epoxide-diol pathway in the biotransformation of mephenytoin.
    Gerber N; Thompson RM; Smith RG; Lynn RK
    Epilepsia; 1979 Jun; 20(3):287-94. PubMed ID: 446437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition of mephenytoin and its metabolite, nirvanol, in epileptic patients.
    Theodore WH; Newmark ME; Desai BT; Kupferberg HJ; Penry JK; Porter RJ; Yonekawa WD
    Neurology; 1984 Aug; 34(8):1100-2. PubMed ID: 6431315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereochemical aspects of the metabolism of 5-ethyl-5-phenylhydantoin (Nirvanol) in the dog.
    Maguire JH; Kraus BL; Butler TC; Dudley KH
    Drug Metab Dispos; 1981; 9(5):393-401. PubMed ID: 6117436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gas chromatographic-mass spectrometric studies on the metabolic fate of ethotoin in man.
    Bius DL; Yonekawa WD; Kupferberg HJ; Cantor F; Dudley KH
    Drug Metab Dispos; 1980; 8(4):223-9. PubMed ID: 6105055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.